6 hours Ago By Defense World Staff
Massmutual Trust Co. FSB ADV lowered its stake in shares of Amgen Inc. ( NASDAQ:AMGN – Free Report ) by 6.
1% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 6,901 shares of the medical research company’s stock after selling 452 shares during the quarter. Massmutual Trust Co.
FSB ADV’s holdings in Amgen were worth $2,224,000 as of its most recent SEC filing. Other hedge funds have also recently added to or reduced their stakes in the company. Strategic Financial Concepts LLC acquired a new position in Amgen during the 2nd quarter valued at about $26,000.
Horizon Financial Services LLC acquired a new position in Amgen during the 1st quarter valued at about $28,000. Hershey Financial Advisers LLC acquired a new position in Amgen during the 2nd quarter valued at about $30,000. nVerses Capital LLC acquired a new position in Amgen during the 2nd quarter valued at about $31,000.
Finally, Bbjs Financial Advisors LLC acquired a new position in Amgen during the 2nd quarter valued at about $33,000. Institutional investors own 76.50% of the company’s stock.
Analyst Ratings Changes AMGN has been the topic of a number of analyst reports. Argus increased their price target on shares of Amgen from $300.00 to $340.
00 and gave the company a “buy” rating in a research report on Thursday, June 27th. Dbs Bank upgraded shares of Amgen to a “strong-buy” rating in a research report on Monday, September 16th. Royal Bank of Canada reiterated an “outperform” rating and issued a $362.
00 price target on shares of Amgen in a research report on Thursday, September 26th. Wells Fargo & Company downgraded shares of Amgen from an “overweight” rating to an “equal weight” rating and raised their target price for the stock from $320.00 to $335.
00 in a report on Wednesday, August 7th. Finally, Jefferies Financial Group restated a “buy” rating and set a $380.00 target price (up from $375.
00) on shares of Amgen in a report on Wednesday, August 7th. One equities research analyst has rated the stock with a sell rating, eleven have issued a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $325.
55. Amgen Stock Down 0.7 % AMGN stock opened at $317.
48 on Friday. The company has a market cap of $170.31 billion, a PE ratio of 45.
35, a price-to-earnings-growth ratio of 2.98 and a beta of 0.61.
The business has a 50-day simple moving average of $327.58 and a 200 day simple moving average of $308.62.
Amgen Inc. has a 52 week low of $249.70 and a 52 week high of $346.
85. The company has a quick ratio of 0.89, a current ratio of 1.
26 and a debt-to-equity ratio of 9.64. Amgen ( NASDAQ:AMGN – Get Free Report ) last released its earnings results on Tuesday, August 6th.
The medical research company reported $4.97 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $5.01 by ($0.
04). The business had revenue of $8.39 billion during the quarter, compared to the consensus estimate of $8.
35 billion. Amgen had a net margin of 10.12% and a return on equity of 161.
72%. The business’s revenue was up 20.1% on a year-over-year basis.
During the same quarter in the prior year, the firm earned $5.00 EPS. Sell-side analysts anticipate that Amgen Inc.
will post 19.49 EPS for the current fiscal year. Amgen Announces Dividend The firm also recently declared a quarterly dividend, which was paid on Tuesday, August 6th.
Stockholders of record on Friday, August 16th were issued a dividend of $2.25 per share. The ex-dividend date was Friday, August 16th.
This represents a $9.00 dividend on an annualized basis and a dividend yield of 2.83%.
Amgen’s dividend payout ratio (DPR) is presently 128.57%. Amgen Profile ( Free Report ) Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide.
The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. Featured Articles Five stocks we like better than Amgen How to Buy Cheap Stocks Step by Step When Is the Best Time to Invest in Mutual Funds? What is the S&P/TSX Index? Is NVIDIA Stock in a Correction or Consolidation? 3 Grocery Stocks That Are Proving They Are Still Essential 3 Oversold Stocks with Big RSI Rebound Potential Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter .
.
